Bravecto Chews For Dogs 22-44 Lbs (10-20 Kg)

Description

Bravecto Chews For Dogs 22-44 Lbs (10-20 Kg) deliver 500 mg of fluralaner, providing a minimum dose of 11.4 mg/lb (25 mg/kg) body weight across the entire weight range. As an isoxazoline-class compound, fluralaner works systemically: once absorbed, it blocks GABA-gated and glutamate-gated chloride channels in the arthropod nervous system, killing parasites when they feed on the dog’s blood rather than through skin-surface exposure. Protection extends across 12 weeks for fleas and four tick species per dose, with the exception of lone star tick (Amblyomma americanum), where the labeled efficacy window is 8 weeks.

Recommended for:

Dogs and puppies weighing 22–44 lbs (10–20 kg), aged 6 months and older.

Indication/Coverage:

For dogs suffering from, or at risk from, flea and tick infestations, Bravecto Chews 22–44 lbs addresses the following parasites and conditions:

• Flea treatment and prevention: Kills adult cat fleas (Ctenocephalides felis) and dog fleas (Ctenocephalides canis) within 8 hours of attachment, with persistent lethal activity maintained across the full 12-week dosing interval.
• Black-legged tick (deer tick) control: Treatment and control of Ixodes scapularis infestations for 12 weeks; this species is the primary vector of Lyme disease in the northeastern and upper midwestern United States.
• American dog tick control: Treatment and control of Dermacentor variabilis for 12 weeks; this species is a confirmed vector of Rocky Mountain spotted fever.
• Brown dog tick control: Treatment and control of Rhipicephalus sanguineus for 12 weeks, with efficacy at the adult stage confirmed at 48 hours post-infestation.
• Asian longhorned tick control: Treatment and control of Haemaphysalis longicornis for 12 weeks; an invasive species now present across multiple U.S. states, with efficacy confirmed at 48 hours post-infestation.
• Lone star tick control: Treatment and control of Amblyomma americanum for 8 weeks in dogs 6 months of age and older; fluralaner does not sustain 90% or greater efficacy against this species beyond week 8, and is not labeled for use in puppies under 6 months for this indication.
• Flea Allergy Dermatitis (FAD) management: Removes the flea populations that trigger allergic responses in sensitized dogs, making fluralaner a pharmacologically sound component of an FAD control strategy where flea source elimination is the clinical goal.
• Environmental flea cycle disruption: Newly emerged fleas that feed on a treated dog are killed before depositing viable eggs, breaking the reinfestation cycle in areas the dog frequents.
• Reduction of tapeworm and tick-borne disease risk: Sustained flea and tick control eliminates the intermediate hosts and vectors responsible for transmitting Dipylidium caninum (tapeworm) and tick-borne pathogens including Borrelia burgdorferi and Rickettsia rickettsii.

Key Benefits:

The following characteristics are drawn directly from the FDA-approved label for Bravecto Chews (fluralaner) 500 mg.

• Mid-weight breed coverage: Labeled for dogs from 22 lbs (10 kg) through 44 lbs (20 kg), encompassing breeds such as Border Collies, Cocker Spaniels, Bulldogs, and Whippets at typical adult weight.
• Five-species tick spectrum: A single 500 mg chew addresses five distinct tick species, covering the primary vectors of Lyme disease, Rocky Mountain spotted fever, and emerging invasive species in a single quarterly dose.
• Systemic bloodstream delivery: Fluralaner circulates via the bloodstream and reaches parasites at the point of feeding, so water exposure, bathing, or coat condition after dosing does not affect efficacy as it would with a topical formulation.
• Flea kill within 8 hours: Adult fleas are eliminated within 8 hours of attachment, limiting the feeding window available for allergen transfer and egg deposition before the parasite is killed.
• 12-week protection per dose: One chew covers a full 12-week interval for fleas and four tick species, requiring only four doses per year for those indications rather than the twelve doses required by monthly oral products.
• Oral chewable format: Administered as a flavored chew rather than a topical spot-on, this formulation suits dogs with skin conditions at the interscapular application site or households where post-application residue contact with children or other animals is a concern.
• FAD lesion improvement: In the U.S. field study, dogs presenting with flea allergy dermatitis showed documented improvement in erythema, alopecia, papules, scales, crusts, and excoriation as a direct outcome of flea population elimination by fluralaner.
• Food-dependent absorption: Fluralaner bioavailability is measurably reduced in the fasted state; administering the chew with food ensures the drug reaches the plasma concentrations necessary for the labeled duration of efficacy.

Caution:

Hazards to Humans

Bravecto Chews are not for human use. Retain each chew in its original blister packaging until the moment of administration, and keep the product out of reach of children at all times. Avoid eating, drinking, or smoking during handling. Wash hands with soap and water immediately after giving the dose.

Hazards to Domestic Animals

Bravecto Chews are for oral administration only. The 22–44 lb variant is labeled for dogs and puppies weighing at least 22 lbs (10 kg) and aged 6 months or older; dogs below either threshold should not receive this tablet. Consult a veterinarian before use in debilitated, aged, pregnant, or lactating animals. Fluralaner is an isoxazoline-class drug associated with neurologic adverse reactions including tremors, ataxia, and seizures, even in dogs without a prior seizure history; exercise caution in dogs with known seizure disorders or neurological conditions. Post-approval reports include adverse events in breeding females. Confirm any concurrent medication combinations with a veterinarian before initiating treatment.

Possible Side Effects:

Monitor your dog attentively in the hours following administration of Bravecto Chews, with particular vigilance after the first dose.

The following reactions were documented in the controlled U.S. field study (182-day observation period, n=224 dogs) and in post-approval adverse drug experience reporting submitted to the FDA/CVM:

• Vomiting: Reported in 7.1% of dogs in the Bravecto group; the most frequently recorded GI sign, typically transient and resolving without intervention.
• Decreased appetite: Reported in 6.7% of Bravecto-group dogs and absent in the active control group, indicating a product-associated pattern at this frequency.
• Lethargy: Reported in 5.4% of field study dogs; the majority of cases resolved without medical treatment during the observation period.
• Diarrhea: Reported in 4.9% of dogs; post-approval surveillance includes cases of bloody diarrhea in a subset of affected animals.
• Polydipsia: Reported in 1.8% of Bravecto-group dogs during the 182-day field study.
• Flatulence: Reported in 1.3% of dogs in the treated group.
• Neurologic signs: Post-approval reporting to the FDA/CVM includes tremors, ataxia, and seizures in dogs receiving isoxazoline-class drugs, including animals with no documented prior seizure history.
• Dermal and allergic reactions: Post-approval reports encompass pruritus, hives, erythema, swelling, and dermatitis presenting as crusts, pustules, or rash.

If any of these signs develop after administration, contact your veterinarian for advice and evaluation. The dog should be examined before the next scheduled dose if any neurologic or allergic signs have occurred.